Navigation Links
Stem cell discovery could lead to improved bone marrow transplants

SANTA CRUZ, CA--Researchers at the University of California, Santa Cruz, have identified a key molecule for establishing blood stem cells in their niche within the bone marrow. The findings, reported in the January issue of Cell Stem Cell, may lead to improvements in the safety and efficiency of bone marrow transplants.

Bone marrow transplants are a type of stem cell therapy used to treat cancers such as lymphoma and leukemia and other blood-related diseases. In a bone marrow transplant, the "active ingredients" are hematopoietic stem cells, which live in the bone marrow and give rise to all the different kinds of mature blood cells. The new study shows that hematopoietic stem cells use a molecule called Robo4 to anchor themselves in the bone marrow.

"Robo4 is a rare molecule that is found only in hematopoietic stem cells and in the endothelial cells of blood vessels," said Camilla Forsberg, an assistant professor of biomolecular engineering in the Baskin School of Engineering at UC Santa Cruz. After earlier work in her lab showed that Robo4 is specific for hematopoietic stem cells, Forsberg set out to discover how it functions.

The discovery that the cells need Robo4 to stay in the bone marrow has potential therapeutic implications. An increasingly common alternative to traditional bone marrow transplants (which require anesthesia for the bone marrow extraction) involves harvesting hematopoietic stem cells from the blood. Repeated injections of drugs are needed to get the stem cells to leave the bone marrow and enter the bloodstream so that they can be collected with a blood draw. A drug that blocks Robo4 could be a safer and more effective way to do this, Forsberg said.

"If we can get specific and efficient inhibition of Robo4, we might be able to mobilize the hematopoietic stem cells to the blood more efficiently," she said. "We're already working on that in the second phase of the project."

Robo4 acts as an adhesion molecule, interacting with other components of the bone marrow to bind the stem cells into their proper niche. Forsberg's lab is trying to find out what molecules bind to Robo4, which could lead to a better understanding of that niche. While other types of stem cells are routinely grown in petri dishes, hematopoietic stem cells are very difficult to grow in the lab. They seem to require the bone marrow environment to function properly, and Forsberg's research might enable researchers to recreate that environment in a petri dish.

Other molecules besides Robo4 are also known to be involved in guiding the localization of hematopoietic stem cells in the bone marrow. Forsberg's results indicate that one of these, called Cxcr4, acts together with Robo4 to retain hematopoietic stem cells in the bone marrow. But the two molecules appear to act through different molecular mechanisms. Inhibition of both molecules may be the best way to achieve efficient mobilization of hematopoietic stem cells, Forsberg said.


Contact: Tim Stephens
University of California - Santa Cruz

Related biology technology :

1. Thomson Reuters and ChemAxon Partner to Help Speed Drug Discovery for Life Science Researchers
2. Gene Discovery Could Increase Value of Non-Food Crops for Industries Outside of Agriculture
3. Discovery of new molecule can lead to more efficient rocket fuel
4. ASCB Launches The Cell: An Image Library(TM) to Inspire Discovery and Improve Human Health
5. Integrated Medical Systems Technology Recognized as Qualified Therapeutic Discovery
6. StemCyte Awarded $488,950 for Advanced Therapeutic Applications of Umbilical Cord Blood Stem Cells from the Qualifying Therapeutic Discovery Project (QTDP)
7. Tomophase Receives Qualifying Therapeutic Discovery Project (QTDP) Award
8. NOVAVAX Awarded Nearly $1 Million in Grants from IRS Under Qualifying Therapeutic Discovery Project
9. PharmAthene Receives Four Therapeutic Discovery Project Grants Totaling Approximately $850,000
10. Lentigen Awarded $1.2 Million by U.S. Government Under the Qualifying Therapeutic Discovery Project
11. Bolder BioTechnology Announces $1.2 Million in Qualifying Therapeutic Discovery Project Grants
Post Your Comments:
(Date:11/30/2015)... Epigenetics Corp. ("Zenith" or the "Company") today announced that it ... Board of Directors to replace Dr. Peter Johann . ... as co-founder of Resverlogix, with expertise in the fields of ... --> Dr. Wong remarked, "I am very excited to ... expertise in epigenetics and the advanced stage of the R&D ...
(Date:11/30/2015)... ... November 30, 2015 , ... Imagine Exhibitions and Universal Partnerships ... opening in March 2016 at Melbourne Museum in Melbourne, Australia. Immediately following the ... American tour dates. The Exhibition is based on Universal Pictures’ Jurassic World, one ...
(Date:11/30/2015)... 2015 Human Longevity, Inc. (HLI), the genomics-based, ... Cypher Genomics, Inc., a leading genome informatics company offering ... solutions. The San Diego -based company ... CEO and Co-founder, Ashley Van Zeeland , Ph.D., who ... details of the deal were not disclosed. ...
(Date:11/30/2015)... , Nov. 30, 2015  HUYA Bioscience International, ... China,s pharmaceutical innovations, today announced it has ... Development Fund (KDDF) to foster collaboration between KDDF and ... and commercialization of healthcare products for the global market. ... an important source of new innovative preclinical and clinical ...
Breaking Biology Technology:
(Date:11/12/2015)...  Arxspan has entered into an agreement with ... use of its ArxLab cloud-based suite of biological ... will support the institute,s efforts to electronically manage ... internally and with external collaborators. The ArxLab suite ... Institute,s electronic laboratory notebook, compound and assay registration, ...
(Date:11/10/2015)... 2015 About signature verification ... to identify and verify the identity of an ... the secure and accurate method of authentication and ... individual because each individual,s signature is highly unique. ... dynamic signature of an individual is compared and ...
(Date:11/2/2015)...  SRI International has been awarded a contract of ... to the National Cancer Institute (NCI) PREVENT Cancer Program ... modern testing and support facilities, and analytical instrumentation to ... studies to evaluate potential cancer prevention drugs. ... Drug Development Program is an NCI-supported pipeline to bring ...
Breaking Biology News(10 mins):